The discovery and development of HIV therapy: The new challenges

Annali dell'Istituto Superiore di Sanita

Volumn 47, Issue 1, 2011, Pages 41-43

  Perno, Carlo Federico ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Antiviral therapy; Evidence based medicine; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS FUSION INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; INTEGRASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ARTICLE; HISTORY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION;

ANTI-HIV AGENTS; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HIV; HIV FUSION INHIBITORS; HIV INFECTIONS; HIV INTEGRASE INHIBITORS; HIV PROTEASE INHIBITORS; HUMANS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 79953068289     PISSN: 00212571     EISSN: None     Source Type: Journal    
DOI: 10.4415/ANN-11-01-09     Document Type: Article

References (7)

1. Hogg R, Lima V, Sterne JA, Grabar S, Battegay M, Bonarek M, D'Arminio Monforte A, Esteve A, Gill MJ, Harris R, Justice A, Hayden A, Lampe F, Mocroft A, Mugavero MJ, Staszewski S, Wasmuth JC, van Sighem A, Kitahata M, Guest J, Egger M, May M. Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies. Lancet 2008;372:266-7.
2. European AIDS Clinical Society. EACS guidelines 2009. Available from: www.europeanaidsclinicalsociety.org/guidelines.asp.
3. Hammer SM, Eron JJ Jr, Reiss P, Schooley RT, Thompson MA, Walmsley S, Cahn P, Fischl MA, Gatell JM, Hirsch MS, Jacobsen DM, Montaner JS, Richman DD, Yeni PG, Volberding PA; International AIDS Society-USA. Antiretroviral treatment of adult HIV infection: 2008 recommendations of the International AIDS Society USA Panel. JAMA 2008;300:555-70.
4. US Department of Health and Human Services. Guidelines for the use of antiretroviral agents in HIV-l-infected adults and adolescents. Washington (DC): US HHS; 2009. p. 1-161. Available from: www.aidsinfo.nih.gov/ContentFiles/ AdultandAdolescentGL.pdf.
5. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, Garren KW, George T, Rooney JF, Brizz B, Lalloo UG, Murphy RL, Swindells S, Havlir D, Mellors JW, AIDS Clinical Trials Group Study A5142 Team. Classsparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008;358:2095-106.
6. Domingo P, Suárez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Muñoz A, Viciana P, Lozano F, Vergara A, Roca B, Garciacute;a Alcalde ML, Cosiacute;n J, Terroacute;n A, Galindo MJ, Geijo P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison from the VACH cohort. J Antimicrob Chemother 2008;61:1348-58. (Pubitemid 351753607)
7. Wood E, Hogg RS, Yip B, Moore D, Harrigan PR, Montaner JS. Superior virological response to boosted protease inhibitor-based highly active antiretroviral therapy in an observational treatment programme. HIV Med 2007;8:80-5. (Pubitemid 46390843)